1.08

5.26% -0.06

After Hours: 1.08

Rani Therapeutics Holdings Inc (RANI)

Overview News Price History Option Chain Financials Discussions Forecast

Rani Therapeutics Holdings Inc stock is traded at $1.08, with a volume of 2.50M. It is down -5.26% in the last 24 hours and down -21.74% over the past month. Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.

Previous Close:

$1.14

Open:

$1.22

24h Volume:

2.50M

Relative Volume:

2.15

Market Cap:

$105.36M

Revenue:

$1.20M

Net Income/Loss:

$-47.60M

P/E Ratio:

-1.3659

EPS:

-0.7907

Net Cash Flow:

$-27.78M

1W Performance:

-6.09%

1M Performance:

-21.74%

6M Performance:

+125.00%

1Y Performance:

-24.48%

1-Day Range:

$1.07

$1.22

1-Week Range:

$1.06

$1.22

52-Week Range:

$0.387

$3.87

Rani Therapeutics Holdings Inc Stock (RANI) Company Profile

Name

Rani Therapeutics Holdings Inc

Sector

Healthcare (1113)

Industry

Biotechnology (623)

Phone

(408) 457-3700

Address

2051 RINGWOOD AVENUE, SAN JOSE

Employee

106

Twitter

Next Earnings Date

2026-03-26

Latest SEC Filings

RANI's Discussions on Twitter

Compare RANI vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RANI Rani Therapeutics Holdings Inc	1.08	111.21M	1.20M	-47.60M	-27.78M	-0.7907
VRTX Vertex Pharmaceuticals Inc	453.74	115.58B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	756.73	79.23B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.16	43.59B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	692.83	43.26B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	147.60	31.97B	606.42M	-1.28B	-997.58M	-6.403

Rani Therapeutics Holdings Inc Stock (RANI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-02-24	Initiated	Oppenheimer	Outperform
Jun-14-24	Initiated	Maxim Group	Buy
Jun-13-24	Initiated	Rodman & Renshaw	Buy
Apr-17-23	Resumed	BTIG Research	Buy
Oct-11-22	Initiated	UBS	Buy
Jul-27-22	Initiated	H.C. Wainwright	Buy
Jun-13-22	Initiated	Wedbush	Outperform

View All

Rani Therapeutics Holdings Inc Stock (RANI) Latest News

05:32 AM

RANI: Major Chugai deal, RT-114 clinical progress, and strengthened finances mark a transformative 2025 - TradingView

05:32 AM

05:20 AM

Earnings call transcript: Rani Therapeutics Q4 2025 sees improved liquidity but misses EPS forecast - Investing.com India

05:20 AM

05:19 AM

RANI: Advanced pipeline, secured major Chugai deal, and extended cash runway into Q4 2027 - TradingView

05:19 AM

04:43 AM

Rani Therapeutics (NASDAQ: RANI) boosts cash, advances oral biologics pipeline - Stock Titan

04:43 AM

04:10 AM

[8-K] Rani Therapeutics Holdings, Inc. Repor... - Stock Titan

04:10 AM

04:05 AM

A pill instead of shots? Rani starts obesity study after $1.085B deal - Stock Titan

04:05 AM

08:05 AM

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

08:05 AM

Mar 25, 2026

Rani Therapeutics Appoints Jesper Hoiland as Head of Strategy to Advance Corporate and Pipeline Prioritization - Bitget

Mar 25, 2026

Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization - The Manila Times

Mar 25, 2026

Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Drive Corporate and Pipeline Development - Quiver Quantitative

Mar 25, 2026

Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization - GlobeNewswire Inc.

Mar 25, 2026

Rani Therapeutics names Jesper Høiland as head of strategy By Investing.com - Investing.com Canada

Mar 25, 2026

Mar 24, 2026

Rani Therapeutics Holdings Inc expected to post a loss of 7 cents a shareEarnings Preview - TradingView

Mar 24, 2026

Mar 23, 2026

Rani Therapeutics (RANI) Expected to Announce Earnings on Monday - MarketBeat

Mar 23, 2026

Mar 22, 2026

If You Invested $1,000 in Rani Therapeutics Holdings, Inc. (RANI) - Stock Titan

Mar 22, 2026

Mar 21, 2026

US Market Recap: Will Rani Therapeutics Holdings Inc outperform during market ralliesFed Meeting & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn

Mar 21, 2026

Analyst Calls: Will Rani Therapeutics Holdings Inc outperform during market ralliesTrade Risk Assessment & Real-Time Stock Entry Alerts - baoquankhu1.vn

Mar 21, 2026

Volatility Watch: Can Rani Therapeutics Holdings Inc beat the S P 5002026 Review & Risk Managed Investment Entry Signals - baoquankhu1.vn

Mar 21, 2026

Mar 20, 2026

Published on: 2026-03-21 04:57:56 - baoquankhu1.vn

Mar 20, 2026

Mar 19, 2026

Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results - The Manila Times

Mar 19, 2026

Mar 18, 2026